Synchronous multicentric giant cell tumor

Bandyopadhyay, Ranjana; Biswas, S.; Bandyopadhyay, Sanjay; Ray, MM

doi:10.4103/0973-1482.63552

Cited by 15 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Giant cell tumor (GCT) of bone is a benign primary neoplasm accounting for 4% to 5% of all primary bone tumors [1–4]. GCT of bone typically presents as a solitary lytic lesion of the metaphyseal-epiphyseal region of a long bone of adults [1] and in nearly 50% of the cases they occur adjacent to the knee joint [3–6]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multicentric Giant Cell Tumor of Bone: Synchronous and Metachronous Presentation

Wirbel

Blümler

Lommel

et al. 2013

Case Reports in Orthopedics

View full text Add to dashboard Cite

A 27-year-old man treated 2.5 years ago for synchronous multicentric giant cell tumor of bone located at the right proximal humerus and the right 5th finger presented now with complaints of pain in his right hip and wrist of two-month duration. Radiology and magnetic resonance revealed multicentric giant cell tumor lesions of the right proximal femur, the left ileum, the right distal radius, and the left distal tibia. The patient has an eighteen-year history of a healed osteosarcoma of the right tibia that was treated with chemotherapy, resection, and allograft reconstruction. A literature review establishes this as the first reported case of a patient with synchronous and metachronous multicentric giant cell tumor who also has a history of osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Multicentric lesions are considered to be more frequently restricted to the metaphyseal or diaphyseal-metaphyseal region of the long bones than solitary lesions, which predominantly involve the metaphysis and the epiphysis [1–4, 6]. …”

Section: Discussionmentioning

confidence: 99%

Multicentric Giant Cell Tumor of Bone: Synchronous and Metachronous Presentation

Wirbel

Blümler

Lommel

et al. 2013

Case Reports in Orthopedics

View full text Add to dashboard Cite

show abstract

“…The bones of the hands and feet are uncommon locations (Fig 6), with a prevalence of less than 2% (15)(16)(17). Multicentric GCT has been reported in less than 1% of cases, with lesions often located in the distal extremities, particularly the hands and feet (18)(19)(20)(21).…”

Section: Uncommon Radiologic Manifestationsmentioning

confidence: 99%

Giant Cell Tumor of Bone: Review, Mimics, and New Developments in Treatment

Chakarun

Forrester²,

Gottsegen³

et al. 2013

RadioGraphics

336

348

View full text Add to dashboard Cite

Giant cell tumor (GCT) of bone is generally a benign tumor composed of mononuclear stromal cells and characteristic multinucleated giant cells that exhibit osteoclastic activity. It usually develops in long bones but can occur in unusual locations. The typical appearance is a lytic lesion with a well-defined but nonsclerotic margin that is eccentric in location, extends near the articular surface, and occurs in patients with closed physes. However, GCT may have aggressive features, including cortical expansion or destruction with a soft-tissue component. Fluid-fluid levels, consistent with secondary formation of aneurysmal bone cysts, are seen in 14% of cases. GCT can mimic or be mimicked by other benign or malignant lesions at both radiologic evaluation and histologic analysis. Rarely, GCT is associated with histologically benign lung metastases or undergoes malignant degeneration. In the past, the mainstay of treatment was surgical, primarily consisting of curettage with cement placement, with recurrence rates of 15%-25%. Recurrence is suggested by development of progressive lucency at the cement-bone interface. Other complications include pathologic fracture and postoperative infection. Denosumab, a monoclonal antibody that targets the osteoclastic activity of GCT, has produced 90% tumor necrosis in early studies, results indicative of promise as a potential adjuvant therapy.

show abstract

“…With respect to treatment of multicentric lesions, it should be noted that the indications for the type of surgery are the same as in the case of a solitary lesion [2,66].…”

Section: Treatment Of Multicentric Lesions Malignant Gctb Pulmonarymentioning

confidence: 99%

“…Multicentric GCTB does not differ from the solitary tumor regarding its radiological, histological, and therapeutic aspects. Radiological and histological characteristics, as well as in the treatment of multicentric GCTB, are not different from that of the solitary lesions [2,66]. TREATMENT GCTB is one of the most discussed bone tumors today.…”

Section: мUlticentric Gctbmentioning

confidence: 99%

Giant cell tumor of bone: current review of morphological, clinical, radiological, and therapeutic characteristics

Georgiev

Slavchev²,

Dimitrova³

et al. 2014

J Clin Exp Invest

View full text Add to dashboard Cite

ÖZETKemiğin dev hücreli tümörü erişkinlerdeki tüm primer kemik tümörlerinin %5'ini oluşturur ve kemik tümörlerinin en güç ve yoğun araştırılanıdır. Bu durum büyük ölçüde tekrarları öngörmeye izin veren tek tip klinik, radyografik, histolojik ve morfolojik özelliklerinin olmayışı nedeniyledir. Dünya Sağlık Örgütü tarafından agresif potansiyeli olan malign bir lezyon olarak sınıflandırılan kemiğin dev hücreli tümörü akciğere metastaz yapar ve malign dejenerasyon veya çok merkezli lokalizasyon gösterir. Tümör genellikle uzun kemiklerde oluşur, ancak alışılmadık lokalizasyonlarda da olabilir. Yaygın semptomu tümör bölgesindeki artan ağrıdır. Standart tedavi küretajdan geniş rezeksiyona kadar değişir ve değişik onkolojik ve fonksiyonel sonuçlar doğurur. Tümör evresine bakılmaksızın, cerrahiyi takip eden ilk 2-3 yılda tekrarlama riski yüksektir. Bu yazıda bu patolojik teşekkülün morfolojik, klinik, radyolojik ve tedavi özellikleri ile ayırıcı tanısı tartışılmıştır.Anahtar kelimeler: Kemiğin dev hücreli tümörü, tanı, tedavi, derleme ABSTRACTGiant cell tumor of bone accounts for about 5% of all primary bone tumors in adults and is still one of the most obscure and intensively examined tumors of bone. This largely results from the lack of uniform clinical, radiographic, histological or morphological aspects that allow prediction of recurrence. Classified by the World Health Organization as "an aggressive, potentially malignant lesion", the giant cell tumor of bone could give lung metastases, could undergo malignant degeneration or could have multicentric localization. It usually develops in long bones but can also occur in unusual locations. The common presenting symptom is increasing pain at the tumor site. Standard treatment ranges from curettage to wide resection, with reports of varying oncological and functional results. The recurrence rate is high during the first 2-3 years after surgery regardless of pre-operative tumor stage. Herein, we discuss the morphological, clinical, radiological, and therapeutic characteristics of this pathologic entity as well as its differential diagnosis. J Clin Exp Invest 2014; 5 (3): 475-485

show abstract

Synchronous multicentric giant cell tumor

Cited by 15 publications

References 6 publications

Multicentric Giant Cell Tumor of Bone: Synchronous and Metachronous Presentation

Multicentric Giant Cell Tumor of Bone: Synchronous and Metachronous Presentation

Giant Cell Tumor of Bone: Review, Mimics, and New Developments in Treatment

Giant cell tumor of bone: current review of morphological, clinical, radiological, and therapeutic characteristics

Contact Info

Product

Resources

About